Stable antibody formulation comprising fianlimab.

CL202601371A1Pending Publication Date: 2026-07-17REGENERON PHARMACEUTICALS INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202601371
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-10-29
Filing Date: 2026-04-28
Publication Date: 2026-07-17

Application Information

Patent Timeline

29 Oct 2024

Priority

28 Apr 2026

Application

CL202601371

17 Jul 2026

Publication

CL202601371A1

IPC: A61K9/08; A61K39/395; A61K47/22; A61K47/26; C07K16/28

CPC: A61K39/39591; A61K9/0019; C07K16/2803; A61K47/183; A61K9/08; A61K2039/545; C07K2317/565; A61K47/22

Inventors: TANG Xiaolin; CHEN Hunter H.

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to the human lymphocyte activation gene 3 (LAG-3). In certain embodiments, the formulations contain, in addition to an anti-LAG-3 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability under stress and during storage.

Need to check novelty before this filing date? Find Prior Art